Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 14,736 shares at $727.17 ($9.8M) on 2022-11-15, disclosed to the SEC on 2022-11-16.
Open-market sale of $9.8M REGN by EVP Research. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 1,360 | $0 | 0.0% |
| 2 | $746.00 | 6,280 | $4.7M | 47.6% |
| 3 | $718.60 | 109 | $78K | 0.8% |
| 4 | $718.60 | 109 | $78K | 0.8% |
| 5 | $719.62 | 336 | $242K | 2.5% |
| 6 | $719.62 | 336 |
| $242K |
| 2.5% |
| 7 | $720.26 | 3 | $2K | 0.0% |
| 8 | $721.74 | 297 | $214K | 2.2% |
| 9 | $721.74 | 297 | $214K | 2.2% |
| 10 | $722.36 | 272 | $196K | 2.0% |
| 11 | $722.36 | 272 | $196K | 2.0% |
| 12 | $723.19 | 57 | $41K | 0.4% |
| 13 | $726.48 | 222 | $161K | 1.6% |
| 14 | $726.48 | 222 | $161K | 1.6% |
| 15 | $727.17 | 333 | $242K | 2.5% |
| 16 | $727.17 | 333 | $242K | 2.5% |
| 17 | $728.44 | 361 | $263K | 2.7% |
| 18 | $728.44 | 361 | $263K | 2.7% |
| 19 | $729.37 | 521 | $380K | 3.9% |
| 20 | $729.37 | 521 | $380K | 3.9% |
| 21 | $730.57 | 315 | $230K | 2.3% |
| 22 | $730.57 | 315 | $230K | 2.3% |
| 23 | $731.49 | 532 | $389K | 4.0% |
| 24 | $731.49 | 532 | $389K | 4.0% |
| 25 | $732.40 | 78 | $57K | 0.6% |
| 26 | $732.40 | 78 | $57K | 0.6% |
| 27 | $733.42 | 21 | $15K | 0.2% |
| 28 | $734.59 | 64 | $47K | 0.5% |
| 29 | $736.40 | 2 | $1K | 0.0% |
| 30 | $741.61 | 66 | $49K | 0.5% |
| 31 | $742.25 | 21 | $16K | 0.2% |
| 32 | $744.01 | 100 | $74K | 0.8% |
| 33 | $749.92 | 10 | $7K | 0.1% |
| Total | $668.17 avg | 14,736 | $9.8M | 100% |
| Filing → |
| REGN | SELL | 2024-03-15 | $11.0M | — | Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |